A warning letter posted Tuesday by the Food and Drug Administration revealed quality control issues with Dexcom’s continuous glucose monitors. The FDA raised concerns with a design change to a ...

Deep-pocketed investors have adopted a bearish approach towards DexCom DXCM, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this ...

The Food and Drug Administration on Tuesday released a warning letter that it sent to medical device company Dexcom on March 4 citing quality issues at the facilities responsible for testing its ...

Cheng Xin / Getty Images DexCom received a warning letter from the Food and Drug Administration following inspections of two of its plants. The maker of glucose monitoring devices said ...

DexCom recently received a warning letter from the FDA, which pointed out issues in manufacturing processes and quality management. While these regulatory developments did not impact its ability ...

Dexcom (Nadsaq:DXCM) announced today that it received a warning letter from the FDA following inspections of two company facilities. The letter followed inspections of the company’s plants in San ...

Dexcom received a warning letter on March 4 after the Food and Drug Administration found problems at facilities in Arizona and California, the company revealed Friday in a securities filing. Dexcom ...

Dexcom has received a warning letter from the FDA, after the agency uncovered issues during two inspections of the continuous glucose monitor maker’s facilities last year. In a filing with the ...

17:02 EST DexCom (DXCM) falls 7% to $71.99 after receiving warning letter from FDA See what stocks are receiving Strong Buy ratings from top-rated analysts. Filter, analyze, and streamline your ...

Citi raised the firm’s price target on DexCom (DXCM) to $104 from $101 and keeps a Buy rating on the shares. The firm adjusted medical technology models post the Q4 reports. The prints “were ...